170 related articles for article (PubMed ID: 31579027)
1. VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies.
Beaton L; Tregidgo HFJ; Znati SA; Forsyth S; Clarkson MJ; Bandula S; Chouhan M; Lowe HL; Zaw Thin M; Hague J; Sharma D; Pollok JM; Davidson BR; Raja J; Munneke G; Stuckey DJ; Bascal ZA; Wilde PE; Cooper S; Ryan S; Czuczman P; Boucher E; Hartley JA; Lewis AL; Jansen M; Meyer T; Sharma RA
JMIR Res Protoc; 2019 Oct; 8(10):e13696. PubMed ID: 31579027
[TBL] [Abstract][Full Text] [Related]
2. Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Beaton L; Tregidgo HFJ; Znati SA; Forsyth S; Counsell N; Clarkson MJ; Bandula S; Chouhan M; Lowe HL; Thin MZ; Hague J; Sharma D; Pollok JM; Davidson BR; Raja J; Munneke G; Stuckey DJ; Bascal ZA; Wilde PE; Cooper S; Ryan S; Czuczman P; Boucher E; Hartley JA; Atkinson D; Lewis AL; Jansen M; Meyer T; Sharma RA
J Vasc Interv Radiol; 2022 Sep; 33(9):1034-1044.e29. PubMed ID: 35526675
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
4. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
5. Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.
Duran R; Namur J; Pascale F; Czuczman P; Bascal Z; Kilpatrick H; Whomsley R; Ryan S; Lewis AL; Denys A
Radiology; 2019 Dec; 293(3):695-703. PubMed ID: 31617791
[TBL] [Abstract][Full Text] [Related]
6. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib-eluting Radiopaque Beads:
Denys A; Czuczman P; Grey D; Bascal Z; Whomsley R; Kilpatrick H; Lewis AL
Theranostics; 2017; 7(8):2164-2176. PubMed ID: 28740542
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
11. Radiopaque drug-eluting embolisation beads as fiducial markers for stereotactic liver radiotherapy.
Beaton L; Daly M; Tregidgo HF; Grimes H; Moinuddin S; Stacey C; Znati S; Hague J; Bascal ZA; Wilde PE; Cooper S; Bandula S; Lewis AL; Clarkson MJ; Sharma RA
Br J Radiol; 2022 Feb; 95(1130):20210594. PubMed ID: 34762499
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
Hagan A; Phillips GJ; Macfarlane WM; Lloyd AW; Czuczman P; Lewis AL
Eur J Pharm Sci; 2017 Apr; 101():22-30. PubMed ID: 28132823
[TBL] [Abstract][Full Text] [Related]
13. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
14.
Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
[TBL] [Abstract][Full Text] [Related]
15. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.
Oshita K; Kobayashi T; Namba Y; Fukuhara S; Matsubara K; Takei D; Nakano R; Okamoto W; Sakai H; Tanimine N; Nakahara T; Kuroda S; Tahara H; Ohira M; Kawaoka T; Ide K; Imamura M; Aikata H; Ohdan H
BMJ Open; 2023 Oct; 13(10):e073797. PubMed ID: 37798025
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?
DePietro DM; Li X; Shamimi-Noori SM
Semin Intervent Radiol; 2024 Feb; 41(1):27-47. PubMed ID: 38495263
[TBL] [Abstract][Full Text] [Related]
19. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Minici R; Ammendola M; Manti F; Siciliano MA; Minici M; Komaei I; Currò G; Laganà D
Front Pharmacol; 2021; 12():634087. PubMed ID: 33897422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
